Subscribe To
Sensei biotherapeutics reports favorable clinical data for sns-101 at 2023 sitc annual meeting
– Clinical dose escalation data for SNS-101 monotherapy show well tolerated safety profile, potentially best-in-class pharmacokinetics, and encourag...
November 3, 2023, 8:05 pm
Ambrx biopharma: potential with recently released prostate cancer data
Ambrx Biopharma Inc. updated data of ARX517 for the treatment of patients with mCRPC shows encouraging anti-tumor activity with ...
October 23, 2023, 6:50 pm
Harpoon therapeutics stock soars on ‘promising' lung cancer drug results
Harpoon Therapeutics Inc shares surged as much as 40% in pre-market trading on Monday after the clinical-stage immunotherapy company announced that it...
October 23, 2023, 9:32 am
Harpoon therapeutics announces updated interim tolerability and response data from phase 1/2 clinical trial of t cell engager hpn328 at esmo congress 2023
Confirmed response rate 35% (11/31), across all tumor types and patient cohorts treated with 1 mg primi...
October 21, 2023, 3:31 pm
Oxford cannabinoid readies for next stage as it safely navigates phase i stduy
Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTC:OCTHF) hailed as a 'major milestone' the successful completion of dosing for all ...
October 10, 2023, 2:22 am
We need to look for hits to specific cohorts not just the consumer broadly: charles schwab's sonders
Hosted by Brian Sullivan, “Last Call” is a fast-paced, entertaining business show that explores the intersection of money, culture and policy. Tun...
October 2, 2023, 8:58 pm
Harpoon therapeutics abstract for hpn217 accepted for poster presentation at the 20th international myeloma society annual meeting
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company d...
September 6, 2023, 11:30 am
Nanoviricides reports progress in phase 1a/1b human clinical trial of nv-cov-2 broad-spectrum antiviral drug
NanoViricides (NYSE-A:NNVC) has reported that the Phase 1a/1b human clinical trial of its broad-spectrum antiviral drug NV-CoV-2 is progressing succes...
August 21, 2023, 8:16 am
Perspective therapeutics reports second quarter fiscal 2023 results and recent business highlights
Phase I/2a clinical trials initiated: VMT-α-NET for neuroendocrine tumors, and VMT01 for melanoma. Preliminary results from initial ...
August 11, 2023, 12:00 pm
The month in closed-end funds: july 2023
For the second consecutive month, equity CEFs (+2.69% on a NAV basis) on average chalked up plus-side performance while their fixed income CEF ...
August 5, 2023, 3:12 pm
Medicenna: presenting data next week plus a clinical update next quarter
MDNA failed to report data from the fifth dosing cohort, of its phase 1/2 ABILITY study of MDNA11, in Q2'23 as expected. The company is instead presen...
August 1, 2023, 3:49 pm
Replimune: the rise of oncolytic virus therapies in cancer treatment
The company's RPx platform, featuring RP1, RP2, and RP3, showcases a comprehensive and innovative approach to cancer treatment. Top-line results from ...
July 9, 2023, 1:22 am
Biomea fusion presents positive clinical data from the initial cohorts of the ongoing phase ii study (covalent-111) of bmf-219 in patients with type 2 diabetes mellitus at the american diabetes associ
Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B,...
June 24, 2023, 1:54 am
Biomea fusion presents positive clinical data from the initial cohorts of the ongoing phase ii study (covalent-111) of bmf-219 in patients with type 2 diabetes mellitus at the american diabetes associ
Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B,...
June 24, 2023, 1:54 am
Biomea fusion presents positive clinical data from the initial cohorts of the ongoing phase ii study (covalent-111) of bmf-219 in patients with type 2 diabetes mellitus at the american diabetes associ
Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B,...
June 24, 2023, 1:54 am
Biomea fusion presents positive clinical data from the initial cohorts of the ongoing phase ii study (covalent-111) of bmf-219 in patients with type 2 diabetes mellitus at the american diabetes associ
Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B,...
June 24, 2023, 1:54 am
Biomea fusion presents positive clinical data from the initial cohorts of the ongoing phase ii study (covalent-111) of bmf-219 in patients with type 2 diabetes mellitus at the american diabetes associ
Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B,...
June 24, 2023, 1:54 am
Biomea fusion presents positive clinical data from the initial cohorts of the ongoing phase ii study (covalent-111) of bmf-219 in patients with type 2 diabetes mellitus at the american diabetes associ
Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B,...
June 24, 2023, 1:54 am
Biomea fusion presents positive clinical data from the initial cohorts of the ongoing phase ii study (covalent-111) of bmf-219 in patients with type 2 diabetes mellitus at the american diabetes associ
Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B,...
June 24, 2023, 1:54 am
Kymera therapeutics’ stat3 degrader kt-333 and irakimid degrader kt-413 demonstrate desired target knockdown and safety with continued dose escalation in ongoing phase i clinical trials
Data shared today on PK/PD and safety from additional KT-333 and KT-413 patient dose escalation cohorts...
June 14, 2023, 6:30 am